STOCK TITAN

Appili Therapeutics Inc - APLIF STOCK NEWS

Welcome to our dedicated news page for Appili Therapeutics (Ticker: APLIF), a resource for investors and traders seeking the latest updates and insights on Appili Therapeutics.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Appili Therapeutics's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Appili Therapeutics's position in the market.

Rhea-AI Summary
Appili Therapeutics Inc. (APLI) issued a correction to its press release 'Appili Therapeutics Reports Fiscal Year 2023 Financial and Operational Results' regarding the expected FDA review completion date and milestone payments from Saptalis. The correct expected date for FDA review completion is Q3 2023, and milestone payments are expected in Q3 and Q4 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.85%
Tags
-
Rhea-AI Summary
Appili Therapeutics Inc. (TSX:APLI; OTCQB: APLIF) announces USPTO publication of patent claims for ATI-1501, a liquid oral reformulation of metronidazole, a widely used oral treatment for parasitic and anaerobic bacterial infections. The patent covers composition and preparation methods through 2039, providing market exclusivity. The FDA has set a PDUFA action date of September 23, 2023, for ATI-1501.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
32%
Tags
none
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
14.81%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
conferences
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
management
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-8.51%
Tags
management
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
27.03%
Tags
none
Appili Therapeutics Inc

OTC:APLIF

APLIF Rankings

APLIF Stock Data

3.52M
106.83M
0.06%
11.84%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
Canada
Halifax